Upstream Bio (NASDAQ:UPB) Rating Lowered to “Strong Sell” at Wall Street Zen

Upstream Bio (NASDAQ:UPB) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Saturday.

A number of other research analysts have also recently commented on UPB. HC Wainwright started coverage on Upstream Bio in a research note on Wednesday, June 3rd. They set a “buy” rating and a $36.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Upstream Bio from $8.00 to $9.00 and gave the stock a “neutral” rating in a research note on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of Upstream Bio in a report on Monday, August 3rd. Truist Financial cut their price objective on Upstream Bio to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Finally, Mizuho reduced their target price on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Upstream Bio presently has a consensus rating of “Hold” and a consensus price target of $29.67.

Upstream Bio Stock Performance

UPB stock opened at $7.07 on Friday. The stock has a market cap of $387.22 million, a PE ratio of -2.44 and a beta of 1.26. Upstream Bio has a 12 month low of $5.85 and a 12 month high of $33.68. The company has a 50-day moving average price of $6.81 and a 200 day moving average price of $9.76.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01. The company had revenue of $0.77 million for the quarter, compared to analyst estimates of $0.56 million. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. Sell-side analysts forecast that Upstream Bio will post -2.87 EPS for the current year.

Hedge Funds Weigh In On Upstream Bio

A number of hedge funds have recently added to or reduced their stakes in UPB. Jennison Associates LLC bought a new stake in shares of Upstream Bio during the fourth quarter valued at approximately $7,842,000. Pictet Asset Management Holding SA bought a new position in Upstream Bio in the fourth quarter worth approximately $20,991,000. UBS Group AG grew its stake in Upstream Bio by 563.4% in the fourth quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock worth $49,039,000 after purchasing an additional 1,533,972 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in Upstream Bio during the 1st quarter worth $1,666,000. Finally, Walleye Capital LLC bought a new stake in Upstream Bio during the 2nd quarter valued at $3,450,000.

More Upstream Bio News

Here are the key news stories impacting Upstream Bio this week:

• Positive Sentiment: JPMorgan raised its price target for Upstream Bio (UPB) from $8 to $9 while maintaining a “Neutral” rating. The revised target implies approximately 27.3% upside from the referenced share price, providing a modest positive catalyst despite the unchanged cautious rating. Benzinga article
• Positive Sentiment: HC Wainwright retained its “Buy” rating and $36 price target, indicating substantial potential upside if Upstream Bio’s pipeline and development plans progress successfully. MarketBeat analyst coverage
• Neutral Sentiment: HC Wainwright’s revised forecasts continue to project losses, including estimated 2026 earnings of negative $3.09 per share and negative $0.79 and $0.82 per share for the third and fourth quarters, respectively. The firm’s “Buy” rating remains unchanged, but the estimates point to a lengthy path toward profitability.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across 2026–2030: 2027 to negative $3.31 from negative $3.09, 2028 to negative $3.13 from negative $2.92, 2029 to negative $3.56 from negative $3.35, and 2030 to negative $3.84 from negative $3.42. These broader expected losses may weigh on investor sentiment and offset the benefit of JPMorgan’s target increase. MarketBeat analyst estimates

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.